A 58-year-old man with osteoarthritis and a history of myocardial infarction 2 years ago presents with chronic knee pain. His physician is considering NSAIDs for pain management. The structure marked **C** in the diagram represents COX-2 selective inhibitors (celecoxib, etoricoxib). Which of the following best explains why COX-2 selective inhibitors, despite their reduced gastrointestinal toxicity, carry an increased cardiovascular risk compared to non-selective NSAIDs?

Explanation

## Why option 1 is right COX-2 selective inhibitors (marked **C**) were designed to preserve COX-1-mediated gastric mucosal protection and thereby reduce GI bleeding by ~50% versus non-selective NSAIDs (CLASS and VIGOR trials). However, this selectivity creates an unintended cardiovascular consequence: COX-2 in vascular endothelium normally produces prostacyclin (PGI₂), a vasodilatory and anti-platelet agent. When COX-2 is selectively inhibited, PGI₂ production falls while COX-1 in platelets remains active, unopposed, and continues to produce thromboxane A₂ (TXA₂)—a vasoconstrictor and pro-aggregatory mediator. This imbalance tilts the hemostatic equilibrium toward thrombosis, explaining the increased risk of myocardial infarction and stroke observed in trials (rofecoxib/Vioxx was withdrawn in 2004 due to an estimated 88,000–140,000 excess cardiovascular events). This mechanism is the cornerstone of COX-2 selective inhibitor cardiotoxicity (KD Tripathi 9e Ch 14; Harrison 21e Ch 467). ## Why each distractor is wrong - **Option 2**: COX-2 selective inhibitors do NOT directly inhibit prostacyclin synthesis; rather, they reduce it by inhibiting the COX-2 enzyme that produces it. The key pathophysiology is the unopposed COX-1 activity, not direct inhibition of endothelial PGI₂ production. - **Option 3**: While NSAIDs in general can cause sodium retention and fluid overload via renal effects, this is not the primary mechanism distinguishing COX-2 selective inhibitors' cardiovascular risk. The prothrombotic imbalance (PGI₂ ↓ vs TXA₂ unopposed) is the specific mechanism. - **Option 4**: COX-2 selective inhibitors do not impair the antiplatelet effects of aspirin; in fact, concurrent use does not explain their intrinsic CV risk. The risk exists independently of aspirin co-administration and stems from the COX-1/COX-2 selectivity imbalance. **High-Yield:** COX-2 selectivity trades GI safety for cardiovascular risk by creating a PGI₂ (vasodilatory) vs TXA₂ (prothrombotic) imbalance—unopposed platelet COX-1 activity drives thrombosis. [cite: KD Tripathi 9e Ch 14; Harrison 21e Ch 467]